great post
a quick off the cuffer......(probably missed a bit here as well)
long term profitability?.....the psychedelic therapy sector needs that rescheduling on psilocybin through the FDA
why specifically psilocybin.....more on that down the post
Projections suggest the sector will potentially realise US2.5 trillion opportunity in capitalisation / profitability and treatment resistive depression and anxiety at at the front of that opportunity....and growing in unmet need.
and the real value in that opportunity is the potential ability to 'heal' rather than simply 'manage' the disease ( my term) which has been the standard of care to date globally.
these guys (below) are currently the early stage 'publicly trading' movers and all three 'companies have negative net debt positions, but only Numinus Wellness Inc has a revenue stream....as such at this stage
FDA approval of PT is about 3 to 5 years out, according to MindMeds CEO, so the companies are going to use the cash to try and get there.....
IHL = going straight for that reschedule trigger for this reason......until you get that 'substance availability' from the FDA....ie that rescheduled psilocybin.....you are just passenger on a train without a clear destination.....many dollars and much research in limbo ( my term again) without a clear end goal objective on returns.......
once rescheduled....very different ball game ( the analogy of GW Pharma and cbd in this respect is fairly drawn imo.....they understood that the research and money of CBD drug development needed to be targeted at an unmet indication in order to be able to clear that drug through FDA scrutiny......brilliant understanding of the way forward in bringing a known substance to the 'commercial pharmaceutical counter' and generate revenue....i see IHL moving on psilocybin drug development / rescheduling in exactly the same light = $$$$$)
so....why psilocybin....
As with CBD.....anecdotal and in fact quite a lot of clinical evidence (efficacy and safety profile) already exists around psilocybin / psilocin generated and recorded prior to Nixons' prohibitionist stance, so the path is already well troden from a research point of view....
Sure others are quite advanced in their research work and drug development / trial work.....that's a good thing as it creates the framework for the regulatory authorities to scrutinise and evaluate far more effectively......it allows IHL the same opportunity without the associated initial costs.....that's a value add right there....quite a large one also....
again, at the risk of sounding like a broken record this is the brilliance of IHL BOD imo......simply understanding the doors to try to push open to generate maximum gain early in the 'psychedelic therapy' space and doing that with a drug candidate that already has an established pharmaceutical characterisation is, for an early stage start up very smart strategically....
granted @David91 the psychedelic therapy 'revenue' opportunity is further down the time horizon than CBD treatments arriving in the regulated space commercially....but perhaps, in psilocybins' case, not as far as some might imagine.
imagine the health outcomes achievable through 'healing' rather than 'condition management'...and globally.....wow!
looking forward to the news flow.
